Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of MLTA3698A versus adalimumab in rheumatoid arthritis
2010-021577-37Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pateclizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Genentech. Primary endpoint: Primary efficacy outcome. Started Oct 2010; status: completed.
02
Drugs
pateclizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-021577-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021577-37.